Florgane 300 mg/ml injektionsvæske, suspension Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

florgane 300 mg/ml injektionsvæske, suspension

emdoka - florfenicol - injektionsvæske, suspension - 300 mg/ml - kvæg, svin

Kelaflor 300 mg/ml injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

kelaflor 300 mg/ml injektionsvæske, opløsning

kela laboratoria n.v. - florfenicol - injektionsvæske, opløsning - 300 mg/ml - kvæg, svin

Norfenicol 300 mg/ml injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

norfenicol 300 mg/ml injektionsvæske, opløsning

norbrook laboratories (ireland) limited - florfenicol - injektionsvæske, opløsning - 300 mg/ml - kvæg, svin

Nuflor Minidose 450 mg/ml injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nuflor minidose 450 mg/ml injektionsvæske, opløsning

intervet international b.v. - florfenicol - injektionsvæske, opløsning - 450 mg/ml - kvæg

Tilmicosol 250 mg/ml koncentrat til oral opløsning til brug i drikkevand Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tilmicosol 250 mg/ml koncentrat til oral opløsning til brug i drikkevand

lavet pharmaceuticals ltd. - tilmicosinphosphat - koncentrat til oral opløsning til brug i drikkevand - 250 mg/ml - fjerkræ, kvæg, svin

VeraSeal Den Europæiske Union - dansk - EMA (European Medicines Agency)

veraseal

instituto grifols, s.a. - humant fibrinogen, human thrombin - hemostase, kirurgisk - antihemorrhagics - understøttende behandling hos voksne, hvor standard kirurgiske teknikker er utilstrækkelige:for forbedring af haemostasisas sutur støtte i karkirurgi.

Tildosin 250 mg/ml opløsning til anvendelse i drikkevand/mælk Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tildosin 250 mg/ml opløsning til anvendelse i drikkevand/mælk

dopharma research b.v. - tilmicosin - opløsning til anvendelse i drikkevand/mælk - 250 mg/ml - fjerkræ, kvæg, svin

Ultomiris Den Europæiske Union - dansk - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.